RSHF in Colorectal Cancer

Inclusion Criteria: * Age \> or = 18 years * Social Insurance * Performance Index \<2 * Life expectancy\> 6 months * adenocarcinoma colorectal (histologically proven) * Metastases (inoperable or recurrent after surgery), * hepatic localization and / or lung (up to 3 if one organ metastasis or 3 in total if the two bodies are metastatic). The largest diameter of the metastasis will \< ou = 6cm for the liver, \< or = 6 cm for the lung. If multiple metastases, the sum of their maximum diameter is 6cm \< ou = the liver, \< ou = 6 cm for the lung. * Lesion (s) measurable (s) and evaluable (s) * CT less than 3 weeks * Patients must have received at least one prior chemotherapy regimen containing 5FU • Patients may have received one or more lines of chemotherapy including irinotecan. * bilirubin \<1.5 x ULN * AST and ALT \<5x ULN * neutrophils\> 1.5x109 / L, platelets\> 100x109 / L, hemoglobin\> 9 g / dL * TP, TCA Normal (only for patients treated with a permanent implant) * Informed consent signed. Exclusion Criteria: * contraindication to the administration of irinotecan. * History of radiotherapy in the thoraco-abdominal-cons indicating further irradiation. * History of other invasive cancer treated in a period of less than 5 years (basal cell carcinoma and non-invasive cervical excepted) * Metastatic disease diffuse or more than three metastases in the liver and / or lung during the natural history of disease (excluding any patient is having a complete radiological response on several metastases although 1-3 residual after treatment ( s) medical (at)). * Location (s) tumor (s) = CTV to less than 12 mm laterally or less than 15 mm in the cranio-caudal, stomach, small intestine, esophagus, trachea, bronchi of right and left pulmonary arteries and right and left. * Pregnancy or breastfeeding. \- Lack of means or refusal to use effective contraception for men or women of childbearing age. * Any other concomitant experimental treatment. * Any other concurrent anticancer therapy, immunotherapy or hormonal therapy. * Monitoring impossible because of psychological, sociological or because of geographical distance.